MedPath

Intraoperative Magnesium Sulfate Administration During Orthotopic Liver Transplantation

Not Applicable
Conditions
Postoperative Pain
Interventions
Drug: isotonic saline
Registration Number
NCT03717467
Lead Sponsor
Fayoum University Hospital
Brief Summary

The aim of study is to assess the effect of intraoperative use of magnesium sulfate in liver donating patients in reducing post-operative morphine requirements in early postoperative 24 hour in adult living liver donor.The authors hypothesize that magnesium sulfate can be used to efficiently reduce postoperative morphine consumption in the early 24 hours postoperatively as evident in other surgery types.

Detailed Description

Introduction A lot of recent trials emphasized that perioperative magnesium sulfate (MgSO4) infusion has general anesthetic properties that could reduce anesthetic drug consumption and postoperative analgesia requirements in several types of surgery. Optimal post-operative pain control is necessary for early mobilization, improved respiratory function, and deep venous thrombosis. Administration of multimodal analgesics could limit the excessive use of systemic opioid analgesia especially (morphine), which has a high rate of postoperative side effects as sedation, respiratory depression, ileus, nausea, vomiting, constipation, urine retention, and itching. Therefore, medications and adjuvant drugs reducing the need for opioids have become widely used as parts of multimodal analgesia. Post-operative pain management begins with pre-operative planning and formulating a pain management plan that is tailored to an individual patient's liver function, respiratory and coagulation status, comorbidities and extent of resection.

Anesthetic technique:

Patients will be premedicated with tablet of alprazolam 0.25 mg the night before and 2 hours before surgery. Upon arrival in operating room usual monitoring will be established including heart rate, blood pressure, electrocardiogram (ECG),and temperature. After induction of anesthesia, an arterial line will be inserted for continuous monitoring of blood pressure and frequent blood gas analysis. End-tidal carbon dioxide (capnography) will be attached. General anesthesia will be administered using propofol 2 mg/kg, morphine 0.1 mg/kg and atracurium besylate 0.5 mg/kg followed by oral endotracheal intubation. Maintenance of general anesthesia with a mixture of isoflurane and 50% oxygen in air, morphine 2 mg/ h, mechanical ventilation will be adjusted to keep arterial oxygen saturation \< 95 % and end-tidal carbon dioxide between 35 and 40 mmHg. Atracurium (0.15 mg/kg) will be administered every 30 min.

Baseline intravenous infusion rate of lactated ringers solution will be set at (6ml/ kg/h) in both groups, additional solution will be infused if required. Magnesium sulfate infusion and anesthetic agents will be discontinued at the end of operation. The postoperative residual neuromuscular blockade will be reversed by using neostigmine 0.04 mg/kg and atropine 0.02 mg/kg. Then the patient will be extubated and transferred to the post-anesthesia care unit (PACU) for 1-hour observation.

Statistical analysis:

Statistical analysis will be done using Statistical Package for Social Sciences (SPSS) version 19 for Windows software. Data will be collected from all patients during and after anesthesia. Descriptive statistics (mean, standard deviation, or median and ranges) will be calculated. Comparative statistics between the two groups will be applied. Unpaired t-test will be used to compare the mean values between the two groups. The Kolmogorov-Smirnov test will be implemented to check the normality of continuous data distribution (P ≤ 0.05) Mann-Whitney-U test will be used to compare difference between the two groups for non-parametric variables (e.g.VAS). While the Chi-square test will be used to compare the categorical variables between both groups. The significant result will be considered when P value was less than (0.05).

Sample size calculations of this trial will be done upon the following assumption, α = 0.05 β = 0.2, effect size will be =0.7.The effect size is calculated by using G\*Power software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, German) and the authors found that 25 patients in each group have a power of 80% and plan to recruit 30 patients per group to account for possible dropout.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Age (18-50).
  • American Society of Anesthesiology (ASA) physical state I or II.
  • Normal serum electrolytes.
Exclusion Criteria
  • Impaired hepatic or renal functions.
  • Various degree of heart block.
  • Hypertension
  • Diabetes
  • Myopathy or any neurological disorder.
  • History of long term opioid use
  • Patients treated with calcium channel blockers
  • Patients with known allergy to drug used.
  • Pregnant woman
  • Obesity (Body Mass Index > 30).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
S groupisotonic salineIsotonic saline as placebo will be given.
M groupMagnesium SulfateMagnesium sulfate will be given
Primary Outcome Measures
NameTimeMethod
Postoperative Morphine consumption24 hours after operation

in mg

Secondary Outcome Measures
NameTimeMethod
Interleukin 8 level in blood24 hours after operation

inflammatory mediator measured from venous blood sample

Mean arterial pressure48 hours after end of surgery

in mm mercury by invasive blood pressure

Assessment of sedation48 hours after end of surgery

By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake

Tumor necrosis factor alpha level in blood24 hours after operation

inflammatory mediator measured from venous blood sample

Incidence of respiratory depression48 hours after operation

as opioid related side effect

Incidence of oversedation48 hours after operation

as opioid related side effect

Incidence of itching48 hours after operation

as opioid related side effect

Incidence of paralytic ileus48 hours after operation

as opioid related side effect

Heart rate48 hours after end of surgery

in beat per minute by electrocardiogram

Patient satisfaction level48 hours after end of surgery

By 5-point scale where 1: very unsatisfactory 2:unsatisfactory 3:neutral 4:satisfactory 5:Excellent

Interleukin 6 level in blood24 hours after operation

inflammatory mediator measured from venous blood sample

Incidence of somnolence48 hours after operation

as opioid related side effect

Morphine consumption48 hours after end of surgery

in milligram

Visual Analog Scale48 hours after end of surgery

Pain score which starting from 0:no pain to 10:Worst pain

Blood serum magnesium concentration15 minutes after operation

from venous blood sample in mg/dl

Incidence of shivering48 hours after operation

as opioid related side effect

Incidence of vomiting48 hours after operation

as opioid related side effect

Incidence of nausea48 hours after operation

as opioid related side effect

Incidence of constipation48 hours after operation

as opioid related side effect

Trial Locations

Locations (1)

Sheikh Zayed hospital

🇪🇬

Giza, Egypt

Sheikh Zayed hospital
🇪🇬Giza, Egypt
Hany M Yassin, MD
Contact
1111363602
hmy00@fayoum.edu.eg
Yasser S Mostafa, MD
Contact
1010509735
ysm03@fayoum.edu.eg
© Copyright 2025. All Rights Reserved by MedPath